An­i­mal health vet Juer­gen Horn makes new an­ti­body play for pets, rak­ing $15M in Se­ries A haul

Zoetis forked over $85 mil­lion in 2017 to ac­quire Nexvet Bio­phar­ma and its pipeline of mon­o­clon­al an­ti­bod­ies. Juer­gen Horn, Nexvet’s for­mer chief prod­uct de­vel­op­ment of­fi­cer, has now se­cured $15 mil­lion for his own bi­o­log­ic com­pa­ny for an­i­mals: In­vetx.

Buoyed by emerg­ing ad­vances in gene ther­a­pies for hu­mans, sci­en­tists have start­ed look­ing at har­ness­ing the tech­nol­o­gy for an­i­mals set­ting up com­pa­nies such as Penn-part­nered Scout Bio and George Church-found­ed Re­ju­ve­nate Bio. But akin to Nexvet, In­vetx is work­ing on lever­ag­ing the time-test­ed sci­ence of mon­o­clon­al an­ti­bod­ies to treat chron­ic dis­eases that af­flict man’s best friend.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER